Acumen Pharmaceuticals, INC. 10-Q Filing

Ticker: ABOS · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1576885

Acumen Pharmaceuticals, INC. 10-Q Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type10-Q
Filed DateAug 12, 2025
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 10-Q filing submitted by Acumen Pharmaceuticals, INC. (ticker: ABOS) to the SEC on Aug 12, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (ich registered Common stock, par value $0.0001 per share ABOS The Nasdaq Global Select).

How long is this filing?

Acumen Pharmaceuticals, INC.'s 10-Q filing is 15 pages with approximately 4,563 words. Estimated reading time is 18 minutes.

Where can I view the full 10-Q filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 4,563 words · 18 min read · ~15 pages · Grade level 17.8 · Accepted 2025-08-12 17:05:33

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Balance Sheets 4 Condensed Statements of Operations and Comprehensive Loss 5 Condensed Statements of Changes in Stockholders' Equity 7 Condensed Statements of Cash Flows 8 Notes to Condensed Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34

Signatures

Signatures 35 1 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: the sufficiency of our existing cash and cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; our ability to obtain funding for our operations, including funding necessary to develop and commercialize sabirnetug, subject to obtaining necessary regulatory approvals; the ability of our clinical trials to demonstrate the safety and efficacy of sabirnetug, and other positive results; the therapeutic potential of sabirnetug, including its potential for improved safety and efficacy as compared to other monoclonal antibodies approved and/or in development, as well as our expectations concerning our ongoing ALTITUDE-AD clinical trial and any future clinical trials we may conduct; the structure, focus, success, cost and timing of our development activities, nonclinical studies and clinical trials, and the reporting of data from those clinical trials; the

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Acumen Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands, except share and per share data) June 30, 2025 December 31, 2024 (unaudited) ASSETS Current assets Cash and cash equivalents $ 36,810 $ 35,627 Marketable securities, short-term 106,559 135,930 Prepaid expenses and other current assets 5,035 6,749 Total current assets 148,404 178,306 Marketable securities, long-term 22,797 59,968 Restricted cash 232 232 Other assets, long-term 464 486 Total assets $ 171,897 $ 238,992 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 2,103 $ 5,648 Accrued clinical trial expenses 11,108 15,344 Accrued expenses and other current liabilities 11,650 6,615 Total current liabilities 24,861 27,607 Debt, long-term 29,882 29,419 Other liabilities, long-term 77 150 Total liabilities 54,820 57,176 Commitments and contingencies (Note 10) Stockholders' equity Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 300,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 60,573,425 and 60,094,083 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 6 6 Additional paid-in capital 511,921 506,985 Accumulated deficit ( 394,873 ) ( 325,127 ) Accumulated other comprehensive income (loss) 23 ( 48 ) Total stockholders' equity 117,077 181,816 Total liabilities and stockholders' equity $ 171,897 $ 238,992 The accompanying notes are an integral part of these unaudited condensed financial statements. 4 Table of Contents Acumen Pharmaceuticals, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses Research and development $ 37,125 $ 19,533 $ 62,391 $ 31,

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing